Loeb Partners Corp’s Moderna MRNA Stock Holding History

Loeb Partners Corp’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-800	Closed	-$16K	–	85
2019 Q1	$16K	Buy	+800	New	+$14.8K	0.33%	69

Other funds holding MRNA

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

RWA

Ropes Wealth Advisors Boston, Massachusetts $515M AUM 21.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return

BPC

Banque Pictet & Cie Geneva 73, Switzerland $14.2B AUM 20.68% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Loeb Partners Corp's MRNA Position: Q2 2019 in Review

Loeb Partners Corp sold out of Moderna (MRNA) in Q2 2019, closing a stake of 800 shares — an estimated $16K sold.

Loeb Partners Corp first reported a position in MRNA in Q1 2019 and held it in 1 quarter. The position peaked at $16K in Q1 2019. 138 funds tracked by Wall St. Rank hold MRNA as of Q2 2019.

Loeb Partners Corp reported no remaining Moderna position as of Q2 2019 after selling out during the quarter.
Loeb Partners Corp sold 800 Moderna shares in Q2 2019, an estimated $16K.
Loeb Partners Corp first reported a position in Moderna in Q1 2019 and held it in 1 quarter.
Loeb Partners Corp's Moderna position peaked at $16K in Q1 2019.
138 funds tracked by Wall St. Rank held Moderna as of Q2 2019.

Based on Loeb Partners Corp's 13F filing for Q2 2019.